How to decide when to drop a crappy plan

Article

In his email, Mike tackles the ongoing question in all of eye care: should I accept (or drop or keep taking) That Crappy Insurance (TCI)? Anyone in optometric practice knows exactly which ones they are.

I recently received an email from my friend and colleague Mike Rothschild, OD, from Carrolton, GA. Mike is a member of the Optometry Times Editorial Advisory Board, authors our practice management department, and heads up Leadership OD, a doctor-to-doctor consulting service. A little-known fact: Mike and I started out practicing in the same small northwest Georgia town. Eventually we both left-I to teach, he to build a mega-practice from scratch in his wife’s hometown.

More from Dr. Bowling: Are optometrists really happy?

In his email, Mike tackles the ongoing question in all of eye care: should I accept (or drop or keep taking) That Crappy Insurance (TCI)? Anyone in optometric practice knows exactly which ones they are. These plans don’t pay enough for the services we provide and place restrictions on what service our patients may have. So we constantly struggle with the “keep or drop” decision, unsure of what to do and worry about the consequences of our decision.

Mike explained that in its simplest form, the decision to be in or out of a given vision plan depends on two factors (does the vision plan pay well, and is the practice schedule full enough?) and can be decided with a simple four-quadrant grid.

This grid yields a keep/drop decision in its simplest form. Other factors, such as the plan’s penetrance rate in your service area and an associated medical plan are other factors to consider. Still, it is a useful device when evaluating the benefit of a vision plan to your practice. I’ve seen practices that take any and every vision plan on the market, thinking that a warm body in the chair is better than none at all, while on the other hand, I’ve never heard an OD say he regretted dropping (insert your favorite TCI here).

More from Dr. Bowling: Oral antibiotics not effective in MGD?

We are all burdened with vision care plans, yet we must prevent our practices from becoming shackled to those that seem to be racing to absolute bargain-basement reimbursements. As Mike Rothschild warns, “If you find yourself cutting corners so you can take more plans, consider that you might be doing a disservice to the people who are willing to choose you over their plan.” Yes, Virginia, they are out there, and they are the ones we all strive to grace our doors.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.